INS and type 2 diabetes mellitus: Sulfonylureas are the drugs of choice in the treatment of type 2 diabetes.[1] Currently, gliclazide, a second-generation sulfonylurea, is preferred in therapy because of its selective inhibitory activity toward pancreatic K+ ATP channels,[2] low incidence of producing severe hypoglycemia[3] and other hemobiological effects.[4] It is well established that sulfonylureas produce insulin secretion and improve tissue utilization of glucose at the cellular level,[5] which was responsible for lowering of the blood glucose level.